Incidence and factors associated with treatment failure in the CLIMB multiple sclerosis cohort study

Journal of the Neurological Sciences

Volumn 284, Issue 1-2, 2009, Pages 116-119

  Gauthier, S A ^a   Glanz, B I ^b   Mandel, M ^c   Tsagkaropoulos, Antonios ^b   Neema, Mohit ^b   Stankiewicz, James ^b   Arora, Ashish ^b   Duan, Yang ^b   Liptak, Zsuzsanna ^b   Egorova, Svetlana ^b   Buckle, Guy J ^b   Bakshi, Rohit ^b   Guttmann, C R G ^b   Khoury, S J ^b   Weiner, H L ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Cohort study; MRI; Multiple sclerosis; Treatment response

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; GADOLINIUM; GLATIRAMER; INTERFERON BETA SERINE; METHYLPREDNISOLONE;

ADULT; ARTICLE; CLINICAL FEATURE; CLINICAL STUDY; COHORT ANALYSIS; CORRELATION ANALYSIS; DIFFUSION WEIGHTED IMAGING; DISABILITY; DISEASE COURSE; DRUG MEGADOSE; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; IMMUNOTHERAPY; INCIDENCE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICIAN; PRIORITY JOURNAL; PROBABILITY; RELAPSE; RISK FACTOR; STATISTICAL ANALYSIS; TREATMENT FAILURE; TREATMENT RESPONSE;

ADULT; CONTRAST MEDIA; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GADOLINIUM; HUMANS; IMMUNOLOGIC FACTORS; INCIDENCE; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PEPTIDES; PROSPECTIVE STUDIES; RISK FACTORS; TREATMENT FAILURE; YOUNG ADULT;

EID: 67849126663     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2009.04.020     Document Type: Article

References (20)

1. The IFNB Multiple sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43 (1993) 655-661
2. Jacobs L.D., Cookfair D.L., Rudick R.A., Herndon R.M., Richert J.R., Salazar A.M., et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39 (1996) 285-294
3. Johnson K.P., Brooks B.R., Cohen J.A., Ford C.C., Goldstein J., Lisak R.P., et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Group. Neurology 45 7 (1995) 1268-1276
4. PRISMS (prevention of relapses and disability by interferon beta-1a subcutaneously in multiple sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352 (1998) 1498-1504
5. Mancardi G.L., Sardanelli F., Parodi R.C., Melani E., Capello E., Inglese M., et al. Effect of copolymer-1 on serial gadolinium-enhanced MRI in relapsing-remitting multiple sclerosis. Neurology 50 4 (1998) 1127-1133
6. Paty D.W., and Li D.K. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group. Neurology 43 4 (1993) 662-667
7. Trojano M., Pellegrini F., Fuiani A., Paolicelli D., Zipoli V., Giovanni Z., et al. New natural history of interferon-a treated relapsing multiple sclerosis. Ann Neurol 61 (2007) 300-306
8. O'Rourke K., Walsh C., Antonelli G., and Hutchinson M. Predicting beta-interferon failure in relapsing-remitting multiple sclerosis. Mult Scler 13 (2007) 336-342
9. Gauthier S.A., Glanz B.I., Mandel M., and Weiner H.L. A model for the comprehensive investigation of a chronic autoimmune disease: the multiple sclerosis CLIMB study. Autoimm Rev 5 8 (2006) 532-536
10. Wei X., Warfield S.K., Zou K.H., Wu Y., Li X., Guimond A., et al. Quantitative analysis of MRI signal abnormalities of brain white matter with high reproducibility and accuracy. J Magn Reson Imaging 15 2 (2002) 203-209
11. Coppola G., Lanzillo R., Florio C., Orefice G., Vivo P., Ascione S., et al. Long-term clinical experience with weekly interferon beta-1a in relapsing multiple sclerosis. Eur J Neurol 13 9 (2006) 1014-1021
12. Goodin D.S. Magnetic resonance imaging as a surrogate outcome of disability in multiple sclerosis: have we been overly harsh in our assessment?. Ann Neurol 59 (2006) 597-605
13. Brex P., Ciccarelli O., O'Riordan J.I., Sailer M., Thompson A.J., and Miller D.H. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. NEJM 346 3 (2002) 158-163
14. Tintore M., Rovira A., Rio J., Nos C., Grive E., Tellez N., et al. Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology 67 6 (2006) 968-972
15. Waubant E., Vukusic S., Gignoux L., Dubief F.D., Achiti I., Blanc S., et al. Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology 61 2 (2003) 184-189
16. Rudick R.A., Lee J.C., Simon J., Ransohoff R.M., and Fisher E. Defining interferon beta response status in multiple sclerosis patients. Ann Neurol 56 4 (2004) 548-555
17. Tomassini V., Paolillo A., Russo P., Giugni E., Prosperini L., Gasperini C., et al. Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis. J Neurol 253 3 (2006) 287-293
18. Pozzilli C., Prosperini L., Sbardella E., De Giglio L., Onesti E., and Tomassini V. Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience. Neurol Sci 26 Suppl 4 (2005) S174-S178
19. Rio J., Nos C., Tintore M., Borras C., Galan I., Comabella M., et al. Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon beta: implications for clinical trials. Ann Neurol 52 4 (2002) 400-406
20. Rio J., Nos C., Tintore M., Tellez N., Galan I., Pelayo R., et al. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Ann Neurol 59 2 (2006) 344-352